Ethical challenges associated with pragmatic and cluster RCTs

14 September 2024 - Pragmatic and cluster RCTs offer opportunities for advancing research but present ethical challenges. ...

Read more →

Why should the FDA focus on pragmatic clinical research?

3 June 2024 - Traditional randomised clinical trials have long been a key tool underpinning drug and device development.  ...

Read more →

Accelerating stakeholder collaboration to enhance the clinical trials environment in the EU

20 March 2024 - The Accelerating Clinical Trials in the EU (ACT EU) initiative has established a multi-stakeholder platform aimed at ...

Read more →

Clinical studies: you can see better with the second arm

6 October 2023 - In a statement to the EMA, the IQWiG emphasised that single-arm studies may be sufficient for ...

Read more →

The use of historical controls in clinical trials

28 September 2023 - A randomised clinical trial is frequently the preferred research design for testing new medical treatments. Randomisation helps ...

Read more →

The changing landscape of clinical trials in Australia

4 September 2023 - Examining the clinical trials landscape in Australia is important for governance and to expand knowledge about trial ...

Read more →

Futility in clinical trials

31 July 2023 - The primary objectives of a confirmatory clinical trial, namely a clinical trial conducted with the intention of ...

Read more →

In a rare move, FDA threatens to fine a company for failing to report clinical trial results

16 August 2023 - For only the fifth time, the FDA recently threatened to fine a company or clinical trial ...

Read more →

Paving the way towards coordinated clinical trials in public health emergencies in the EU

25 July 2023 - EMA has published a report from a workshop that collected insights and suggestions for possible EU level ...

Read more →

Evidence of lack of treatment efficacy derived from statistically non-significant results of randomised clinical trials

20 June 2023 - Many randomised clinical trials yield statistically non-significant results. Such results are difficult to interpret within the dominant ...

Read more →

FDA announces additional steps to modernise clinical trials

6 June 2023 - Agency requesting feedback on the draft recommendations and how they should be applied to increasingly diverse trial ...

Read more →

FDA considers new efficacy endpoint for diabetes drugs

31 May 2023 - The US FDA on Friday released an updated draft guidance to help sponsors demonstrate efficacy for ...

Read more →

The FDA is ignoring patients in clinical trials

28 May 2023 - Imagine having two daughters who both have a rare disease and watching them struggle — to ...

Read more →

Adjusting for covariates in randomized clinical trials for drugs and biological products

26 May 2023 - This final guidance describes FDA’s current recommendations regarding adjusting for covariates in the statistical analysis of randomised ...

Read more →

The role of disclosures: helping to understand oncology clinical trial endpoints

18 May 2023 - FDA researchers wanted to see whether consumers understand oncology endpoints in DTC television ads, and whether disclosures ...

Read more →